Staff Reports
Representative Tom Kean Jr. returned to the House floor this week and did something most politicians avoid: he told the truth about a private medical struggle. Kean said he was hospitalized and treated for depression after being absent from Congress for months. That admission matters for his constituents, for the politics of a tight House, and for the national debate around HHS’s new MAHA Action Plan on mental health and “deprescribing.”
Kean’s return and the truth about depression
Rep. Tom Kean Jr. stood before colleagues and explained why he missed more than 100 roll‑call votes: he was fighting real depression. “Depression is so much more than feeling sad,” he said. That plain language helped remove a little of the stigma that still clings to mental illness. Political opponents will use absences in a campaign — that’s politics — but Kean’s choice to be open gave voters a clear picture instead of vague excuses. Voters deserve both honesty and representation, and one can be true without sacrificing the other.
MAHA, deprescribing, and where the government shouldn’t overstep
Health and Human Services Secretary Robert F. Kennedy Jr.’s MAHA Action Plan wants to curb psychiatric overprescribing and push more “deprescribing” conversations between doctors and patients. That goal — more oversight, more informed consent, more funding for therapy — sounds sensible until Washington starts dictating clinical decisions. A federal push to change prescribing habits can help some patients, but it can also risk abrupt cuts to medications where they are needed. If MAHA becomes a one‑size‑fits‑all rulebook, it will do more harm than good. We should welcome better care, not bureaucrats telling doctors what to do from an office far from the exam room.
Where Kean’s story and MAHA intersect
Kean’s case illustrates both sides. His hospitalization and recovery show that depression is a serious, treatable medical condition. At the same time, his experience should warn policymakers: treatment choices must stay with patients and clinicians. MAHA’s focus on shared decision‑making and funding for tapering conversations is reasonable on paper, but federal programs can wobble into coercion. If MAHA expands access to therapy and non‑drug treatments while protecting clinicians’ judgment, it will help. If it becomes a way to shrink medication access without alternatives, it will fail patients.
Politics, accountability, and a simple ask
Finally, Kean’s story is also about accountability. This district deserves a congressman who shows up and explains himself. Transparency about health is welcome; disappearing without clear communication is not. Republicans should defend a colleague’s privacy and progress, but they should also insist on clear representation for voters. Keep the compassion. Keep the standards. And for heaven’s sake, keep Congress focused on real problems instead of turning every medical case into a political cudgel.
